PT1454992E - Ensaio de quinase do linfoma anaplastico, reagentes e composicoes - Google Patents

Ensaio de quinase do linfoma anaplastico, reagentes e composicoes

Info

Publication number
PT1454992E
PT1454992E PT03005186T PT03005186T PT1454992E PT 1454992 E PT1454992 E PT 1454992E PT 03005186 T PT03005186 T PT 03005186T PT 03005186 T PT03005186 T PT 03005186T PT 1454992 E PT1454992 E PT 1454992E
Authority
PT
Portugal
Prior art keywords
reagents
compositions
kinase
test
anaplastic lymphoma
Prior art date
Application number
PT03005186T
Other languages
English (en)
Inventor
Lorenzo A Pinna
Donella-Deana Arianna
Marin Oriano
Mologni Luca
Gunby Rosalind
Gambacorti Passerini Carlo
Scapozza Leonardo
Original Assignee
Ist Naz Stud Cura Dei Tumori
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ist Naz Stud Cura Dei Tumori filed Critical Ist Naz Stud Cura Dei Tumori
Publication of PT1454992E publication Critical patent/PT1454992E/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10Transferases (2.)
    • C12N9/12Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines having two or more nitrogen atoms in the same ring, e.g. oxadiazines
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • G01N2500/04Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
PT03005186T 2003-03-07 2003-03-07 Ensaio de quinase do linfoma anaplastico, reagentes e composicoes PT1454992E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP03005186A EP1454992B1 (en) 2003-03-07 2003-03-07 Anaplastic lymphoma kinase assay, reagents and compositions thereof

Publications (1)

Publication Number Publication Date
PT1454992E true PT1454992E (pt) 2006-09-29

Family

ID=32798804

Family Applications (1)

Application Number Title Priority Date Filing Date
PT03005186T PT1454992E (pt) 2003-03-07 2003-03-07 Ensaio de quinase do linfoma anaplastico, reagentes e composicoes

Country Status (15)

Country Link
US (1) US20070031907A1 (pt)
EP (1) EP1454992B1 (pt)
JP (1) JP2006519800A (pt)
CN (1) CN100345978C (pt)
AT (1) ATE328112T1 (pt)
CA (1) CA2518094A1 (pt)
CY (1) CY1106115T1 (pt)
DE (1) DE60305634T2 (pt)
DK (1) DK1454992T3 (pt)
ES (1) ES2263862T3 (pt)
HK (1) HK1068154A1 (pt)
IL (1) IL170669A0 (pt)
PT (1) PT1454992E (pt)
SI (1) SI1454992T1 (pt)
WO (1) WO2004079326A2 (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8168383B2 (en) 2006-04-14 2012-05-01 Cell Signaling Technology, Inc. Gene defects and mutant ALK kinase in human solid tumors
SI2450437T1 (sl) 2006-04-14 2017-12-29 Cell Signaling Technology Inc. Okvarjenost genov in mutantna ALK kinaza v človeških solidnih tumorjih
EP2107054A1 (en) 2008-04-01 2009-10-07 Università Degli Studi Di Milano - Bicocca Antiproliferative compounds and therapeutic uses thereof
US8871753B2 (en) 2008-04-24 2014-10-28 Incyte Corporation Macrocyclic compounds and their use as kinase inhibitors
EP2161271A1 (en) 2008-09-08 2010-03-10 Università Degli Studi Di Milano - Bicocca Alpha-carboline inhibitors of NMP-ALK, RET, and Bcr-Abl
US8765727B2 (en) 2009-01-23 2014-07-01 Incyte Corporation Macrocyclic compounds and their use as kinase inhibitors
DK2975024T3 (en) * 2009-06-10 2018-04-23 Chugai Pharmaceutical Co Ltd Tetracyclic compounds
CN101955995B (zh) * 2010-06-17 2013-06-26 江苏迈迪基因生物科技有限公司 淋巴瘤相关的融合基因的诊断试剂盒
WO2012019132A2 (en) 2010-08-06 2012-02-09 Cell Signaling Technology, Inc. Anaplastic lymphoma kinase in kidney cancer
EP2606886B1 (en) 2010-08-20 2020-01-08 Chugai Seiyaku Kabushiki Kaisha Composition comprising tetracyclic compound
JP6445426B2 (ja) 2012-05-10 2018-12-26 ザ ジェネラル ホスピタル コーポレイション ヌクレオチド配列を決定する方法
CN111388478A (zh) 2012-09-25 2020-07-10 中外制药株式会社 Ret抑制剂
WO2014128235A1 (en) 2013-02-22 2014-08-28 F. Hoffmann-La Roche Ag Methods of treating cancer and preventing drug resistance
JP7016215B2 (ja) 2014-01-27 2022-02-04 ザ ジェネラル ホスピタル コーポレイション 配列決定のために核酸を調製する方法
AR100187A1 (es) 2014-04-25 2016-09-14 Chugai Pharmaceutical Co Ltd Composición farmacéutica que contiene un inhibidor de alk (quinasa de linfoma anaplásico)
US9714229B2 (en) 2014-04-25 2017-07-25 Chugai Seiyaku Kabushiki Kaisha Crystal of tetracyclic compound
TWI765410B (zh) 2014-08-08 2022-05-21 日商中外製藥股份有限公司 4環性化合物的非晶質體的用途
WO2016114375A1 (ja) 2015-01-16 2016-07-21 中外製薬株式会社 併用医薬
EP4353830A2 (en) 2016-09-15 2024-04-17 ArcherDX, LLC Methods of nucleic acid sample preparation for analysis of cell-free dna
EP3512947B1 (en) 2016-09-15 2021-10-20 ArcherDX, LLC Methods of nucleic acid sample preparation
CN110191959B (zh) 2016-11-02 2024-04-09 阿谢尔德克斯有限责任公司 用于免疫组库测序的核酸样品制备方法
CN112585126B (zh) 2018-09-04 2024-05-07 中外制药株式会社 四环化合物的制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05126833A (ja) * 1991-10-31 1993-05-21 Tosoh Corp チロシンキナ−ゼ活性の免疫化学的測定法及びそのキツト
AU4281393A (en) * 1992-04-10 1993-11-18 Dana-Farber Cancer Institute, Inc. Activation-state-specific phosphoprotein immunodetection
ES2136103T3 (es) * 1992-06-22 1999-11-16 Kyowa Hakko Kogyo Kk Procedimiento para la preparacion de derivados de estaurosporina.
GB9314271D0 (en) * 1993-07-09 1993-08-18 Inst Of Cancer The Research Cell growth factor receptors
DK0730740T3 (da) * 1993-11-23 1998-09-28 Genentech Inc Kinasereceptoraktiveringsassay
US6001621A (en) * 1993-11-23 1999-12-14 Genetech, Inc. Protein tyrosine kinases
US5529925A (en) * 1993-12-03 1996-06-25 St. Jude Children's Research Hospital Nucleic acid sequences and fusion proteins present in human t(2;5) lymphoma
US5763198A (en) * 1994-07-22 1998-06-09 Sugen, Inc. Screening assays for compounds
US5759787A (en) * 1996-08-26 1998-06-02 Tularik Inc. Kinase assay
WO1998049317A2 (en) * 1997-04-28 1998-11-05 Sugen, Inc. Diagnosis and treatment of phosphatase- 0r kinase-related disorders
WO2001004125A1 (fr) * 1999-07-13 2001-01-18 Kyowa Hakko Kogyo Co., Ltd. Derives de staurosporine

Also Published As

Publication number Publication date
CN100345978C (zh) 2007-10-31
CA2518094A1 (en) 2004-09-16
ATE328112T1 (de) 2006-06-15
DE60305634D1 (de) 2006-07-06
ES2263862T3 (es) 2006-12-16
HK1068154A1 (en) 2005-04-22
EP1454992A1 (en) 2004-09-08
CN1756850A (zh) 2006-04-05
JP2006519800A (ja) 2006-08-31
WO2004079326A2 (en) 2004-09-16
US20070031907A1 (en) 2007-02-08
EP1454992B1 (en) 2006-05-31
WO2004079326A3 (en) 2004-12-09
DK1454992T3 (da) 2006-10-02
IL170669A0 (en) 2011-08-01
CY1106115T1 (el) 2011-06-08
DE60305634T2 (de) 2006-09-21
SI1454992T1 (sl) 2006-10-31

Similar Documents

Publication Publication Date Title
IL170669A0 (en) Anaplastic lymphoma kinase assay, reagents and compositions thereof
WO2005111212A3 (en) Biological bar code
DK1706424T3 (da) FC-region varianter
ATE269295T1 (de) Btk inhibitoren und verfahren zur identifizierung und verwendung
EA200501563A1 (ru) Пролекарства ингибиторов киназы pi-3
ATE419253T1 (de) Inhibitoren von thienopyridin- und furopyridinkinase
WO2005012574A3 (en) Biological bar-code
DK1847611T3 (da) Rhamnose-inducerbart ekspressionssystem
EP1700120A4 (en) MARKER FOR OPTICAL NEUROMYELITIS
BR0215360A (pt) Derivados de indolina úteis como inibidores de proteìna quinase
ATE494548T1 (de) Reinigung, charakterisierung und wiederherstellung einer ubiquitin-e3-ligase
HK1080074A1 (zh) 作為酪氨酸蛋白激酶抑制劑的4,6-二氨基取代-2-[氧基或氨氧基]-[1,3,5]三嗪
WO2002047535A3 (en) High throughput assay to detect inhibitors of the map kinase pathway
ATE413884T1 (de) Beta-secretase-substrat und seine verwendung
WO2004050842A3 (en) Atm kinase compositions and methods
DE602006021548D1 (de) Probenlyse und beschichtung einer reaktionsoberfläche
WO2002053743A3 (en) Mammalian tribbles signaling pathways and methods and reagents related thereto
MA29565B1 (fr) Combinaison de composes de pyrimidylaminobenzamide et imatinib permettant de traiter ou de prevenir les maladies proliferatives
WO2007033374A3 (en) Pharmaceutical compositions and methods using temozolomide and a protein kinase inhibitor
DK1224222T3 (da) Chemokinreceptor
DK1328657T3 (da) Proces til påvisning af serin-/threoninkinaseaktivitet
WO2005003388A3 (en) Fluorescence assays for nucleic acid polymerase activity
DE60329931D1 (de) Fprl1-liganden und deren verwendung
NO20013748D0 (no) Ny analyse
AU2003293303A1 (en) Screening assay for identifying agents that modulate pak kinase or cd45 tyrosine phosphatase activity